skip to content

Trading statements

BTG revenue at or above upper end of guidance

06 April 2017 08:28

BTG, the specialist healthcare company, said it expected revenue for the year ended 31 March to be at or above the upper end of the guidance range of £535m - £565m.

Chief executive Louise Makin said: "Our business has performed well this year.

"We have made significant progress in executing our strategy to become a leading provider of Interventional Medicine therapies.

"We have expanded the portfolio both organically and through acquisition and have delivered good revenue growth.

"A strong performance from TheraSphere and the addition of Galil Medical have helped cement our leadership in Interventional Oncology.

"EKOS has continued to increase market penetration, and we have achieved important milestones in our earlier stage businesses.

" There is good momentum across our business and we start the new financial year with confidence."

At 8:28am: (LON:BTG) BTG PLC share price was +27.75p at 617.75p

Story provided by StockMarketWire.com

Related Company: BTG

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

-

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.